Antithrombotic Therapy in Patients with Malignant Lymphoproliferative Disorders Treated with Ibrutinib

Background. Antithrombotic therapy in chronic lymphocytic leukemia (CLL) patients is challenging, as this category of patients is initially characterized by high risk of hemorrhagic complications. The use of ibrutinib influencing the platelet function constitutes an additional bleeding risk. A cruci...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Elena Ivanovna Emelina, G. E. Gendlin, I. G. Nikitin
Aineistotyyppi:	Artigo
Kieli:	Russo
Julkaistu:	Practical Medicine Publishing House 2019-10-01
Sarja:	Клиническая онкогематология
Aiheet:	ibrutinib chronic lymphocytic leukemia antithrombotic therapy dual antiplatelet therapy atrial fibrillation coronary stenting on ibrutinib therapy new oral anticoagulants rivaroxaban dabigatran apixaban
Linkit:	https://bloodjournal.ru/index.php/coh/article/view/342
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!